Private equity firm EQT is acquiring in-silico drug development service provider Certara from Arsenal Capital Partners, a deal that values the CRO at $850 million, Arsenal announced on Tuesday.
Arsenal will retain an unspecified minority stake in Certara, and the company’s current management team, including CEO Edmundo Muniz, M.D., Ph.D., who joined the company in June 2014 from Kirax, will stay on.
Certara is known for its drug development modeling software and regulatory services. Founded in 2008 from a merger between drug discovery informatics provider Tripos and clinical software and regulatory services specialist Pharsight, the company’s current expertise was built through a series of seemingly ceaseless acquisitions:
Thanks to its acquisitions, the services provided by the Princeton, New Jersey-based CRO now span from physiologically based pharmacokinetic modeling and simulation to pharmacometrics to commercial optimization and regulatory writing.
The company, through 19 offices in four continents, serves 1,200 commercial companies, 250 academic institutions and almost all major regulatory agencies. More than 500 employees work for the company, with 100 scientists in in-silico drug development practice and 120 in the regulatory writing section.
This marks EQT’s second major investment in the U.S. healthcare sector, following a $2.35 billion deal to buy up Press Ganey Holdings, a provider of patient satisfaction surveys, according to Reuters.
The CRO realm is nothing short of dealmaking these days, witnessing such megamerger deals as the $7.4 billion union between InVentiv Health and INC Research, and $17.6 billion between Quintiles and IMS Health. Parexel is also being taken private by Pamplona Capital Management for around $5 billion, a deal announced in late June.
By Angus Liu
Source: Fierce Biotech
Novadiscovery uses its so-called JINKO platform that runs disease models on virtual patients to support decision-making and de-risk clinical development.
The pharma is pledging $3.2 million over two years to the Human Rights Campaign, the largest lesbian, gay, bisexual, transgender and queer (LGBTQ+) civil rights organization in the U.S.
In collaboration with Genmab, a new anthropological postdoc project at the Department of Anthropology will now explore and help develop the company’s efforts to ensure a diverse and inclusive workplace.